“According to a new report published by Introspective Market Research, titled, AI in Genomics Market by Component, Application, and End User, the Global AI in Genomics Market Size Was Valued at USD 64.70 Billion in 2024 and is Projected to Reach USD 253.06 Billion by 2035, Growing at a CAGR of 13.2% from 2025–2035.”
The AI in Genomics market represents the convergence of artificial intelligence technologies with genomic research to accelerate data analysis, interpretation, and clinical decision-making. AI-powered tools enable faster genome sequencing analysis, variant identification, gene expression profiling, and disease association studies compared to traditional bioinformatics approaches. These solutions significantly reduce analysis time and cost while improving accuracy, scalability, and predictive insights.
AI in genomics is widely used across drug discovery, precision medicine, oncology diagnostics, rare disease research, and agricultural genomics. By leveraging machine learning, deep learning, and advanced analytics, AI-driven genomic platforms support personalized treatment planning and biomarker discovery, making them essential for modern healthcare and life science research.
Growing investments in genomics research, declining sequencing costs, and rising demand for precision medicine are collectively transforming AI in genomics into a critical enabler of next-generation healthcare and biotechnology innovation worldwide.
Market Segmentation
The AI in Genomics Market is segmented into Component, Application, and End User.
- By Component, the market is categorized into Software, Hardware, and Services.
- By Application, the market is categorized into Drug Discovery & Development, Diagnostics, Precision Medicine, Genomic Data Management, and Other Applications.
- By End User, the market is categorized into Pharmaceutical & Biotechnology Companies, Research Institutes & Academic Centers, Healthcare Providers, and Others.
Growth Driver
One of the key growth drivers of the AI in Genomics market is the rapid expansion of precision medicine and personalized healthcare. AI algorithms enable the analysis of massive genomic datasets to identify patient-specific genetic variations, improving disease prediction and treatment outcomes. The growing prevalence of cancer, rare genetic disorders, and chronic diseases has increased the demand for genomics-driven diagnostics and therapeutics. As healthcare systems increasingly shift toward data-driven and patient-centric care models, AI-powered genomic solutions are becoming indispensable for faster and more accurate clinical insights.
Market Opportunity
A major market opportunity lies in the integration of AI in drug discovery and development workflows. AI-driven genomics platforms significantly shorten drug development timelines by identifying novel drug targets, predicting drug responses, and optimizing clinical trial design. Pharmaceutical companies are increasingly adopting AI-enabled genomic analytics to reduce R&D costs and improve success rates. Additionally, emerging economies present strong growth potential due to expanding genomics infrastructure, government funding, and increasing adoption of AI technologies in healthcare and life sciences.
Detailed Segmentation
AI in Genomics Market, Segmentation
The AI in Genomics Market is segmented on the basis of Component, Application, and End User.
Component
The Component segment is further classified into Software, Hardware, and Services. Among these, the Software sub-segment accounted for the highest market share in 2024. AI-driven genomics software platforms enable advanced data analysis, visualization, and interpretation of complex genomic datasets. These solutions support scalable cloud-based deployment, continuous algorithm updates, and seamless integration with sequencing technologies, making them highly preferred across research and clinical settings.
Application
The Application segment is further classified into Drug Discovery & Development, Diagnostics, Precision Medicine, and Genomic Data Management. Among these, the Drug Discovery & Development sub-segment accounted for the highest market share in 2024. AI in genomics accelerates target identification, biomarker discovery, and lead optimization, significantly reducing development timelines and improving drug efficacy, especially in oncology and rare disease therapeutics.
Some of The Leading/Active Market Players Are-
• Illumina (US)
• Thermo Fisher Scientific (US)
• NVIDIA (US)
• Google DeepMind (UK)
• IBM (US)
• Microsoft (US)
• Amazon Web Services (US)
• Roche (Switzerland)
• BGI Genomics (China)
• SOPHiA GENETICS (Switzerland)
• and other active players.
Key Industry Developments
In March 2024, major genomics companies expanded AI-powered platforms to enhance multi-omics data analysis and clinical decision support.
These developments focus on integrating AI algorithms with large-scale genomic datasets to improve diagnostic accuracy, accelerate research workflows, and enable personalized treatment strategies across oncology and rare disease applications.
In October 2024, leading cloud and AI providers partnered with pharmaceutical companies to deploy AI-driven genomics solutions for drug discovery.
These collaborations aim to leverage cloud-based AI infrastructure to optimize genomic data processing, reduce R&D timelines, and enhance scalability for global life science research initiatives.
Key Findings of the Study
• Software and drug discovery segments dominate the market
• North America leads due to advanced genomics infrastructure
• Precision medicine is a major growth driver
• AI-driven drug development is a key emerging trend
